Beijing Jishuitan Hospital , is a large-scaled first-level hospital in Beijing, focusing mainly on orthopaedics and burn surgery. Founded in 1956, the hospital now has around 1000 beds. Its performance in medical care, teaching and researching led to it becoming the Fourth Medical College of Peking University.

During the past decade, Beijing Jishuitan hospital conducted 44 clinical trials. In the 10-year time frame, 44 clinical trials started and 3 clinical trials were completed, i.e. on average, 6.8% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 3 clinical trials were completed. i.e. 11.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Beijing Jishuitan hospital" #1 sponsor was "Beijing Jishuitan Hospital" with 16 trials, followed by "Peking University First Hospital" with 6 trials sponsored, "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 4 trials sponsored, "Shanghai JMT-Bio Inc." with 2 trials sponsored and "Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd." with 2 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Beijing Jishuitan hospital" #1 collaborator was "Beijing Jishuitan Hospital" with 8 trials as a collaborator, "Chinese PLA General Hospital" with 3 trials as a collaborator, "Aerospace 731 Hospital" with 2 trials as a collaborator, "Beijing Jingmei Group General Hospital" with 2 trials as a collaborator and "Beijing Luhe Hospital" with 2 trials as a collaborator. Other collaborators include 45 different institutions and companies that were collaborators in the rest 50 trials.

According to Clinical.Site data, the most researched conditions in "Beijing Jishuitan hospital" are "Postoperative Delirium" (4 trials), "Dexmedetomidine" (3 trials), "Elderly" (3 trials), "Osteoporosis" (3 trials) and "Degenerative Disc Disease" (2 trials). Many other conditions were trialed in "Beijing Jishuitan hospital" in a lesser frequency.

Most popular intervention types in "Beijing Jishuitan hospital" are "Drug" (20 trials), "Device" (11 trials), "Procedure" (9 trials), "Other" (4 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Dexmedetomidine" (3 trials), "Anlotinib" (2 trials), "609A" (1 trials) and "AGA111" (1 trials). Other intervention names were less common.

The vast majority of trials in "Beijing Jishuitan hospital" are 54 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are 22 active trials in "Beijing Jishuitan hospital". 6 are not yet recruiting, 10 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 21 completed trials in Beijing Jishuitan hospital, 1 suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Beijing Jishuitan hospital, 7 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 16 trials that are defined as “Not Applicable".